No black box warning on record for Portrazza

As of the latest FDA labeling reviewed, Portrazza (NECITUMUMAB) does not carry a black box warning. Standard warnings and precautions still apply — see the full Portrazza medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Cardiopulmonary Arrest : Closely monitor serum electrolytes during and after PORTRAZZA. ( 5.1 ) Hypomagnesemia : Monitor prior to each infusion and for at least 8 weeks following the completion of PORTRAZZA. Withhold PORTRAZZA for Grade 3 or 4 electrolyte abnormalities; subsequent cycles of PORTRAZZA may be administered in these patients once electrolyte abnormalities ha

No black box warning on record for Portrazza

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Cardiopulmonary Arrest : Closely monitor serum electrolytes during and after PORTRAZZA. ( 5.1 ) Hypomagnesemia : Monitor prior to each infusion and for at least 8 weeks following the completion of PORTRAZZA. Withhold PORTRAZZA for Grade 3 or 4 electrolyte abnormalities; subsequent cycles of PORTRAZZA may be administered in these patients once electrolyte abnormalities ha

Portrazza Black Box Warning

No black box warning on record for Portrazza

Other warnings & precautions

Portrazza Black Box Warning

No black box warning on record for Portrazza

Other warnings & precautions